Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enliven Therapeutics (ELVN) Current Assets (2019 - 2026)

Enliven Therapeutics has reported Current Assets over the past 8 years, most recently at $463.1 million for Q1 2026.

  • Quarterly results put Current Assets at $463.1 million for Q1 2026, up 57.36% from a year ago — trailing twelve months through Mar 2026 was $463.1 million (up 57.36% YoY), and the annual figure for FY2025 was $474.9 million, up 49.27%.
  • Current Assets reached $463.1 million in Q1 2026 per ELVN's latest filing, down from $474.9 million in the prior quarter.
  • Across five years, Current Assets topped out at $495.6 million in Q2 2025 and bottomed at $59.1 million in Q3 2022.
  • Median Current Assets over the past 5 years was $297.0 million (2024), compared with a mean of $286.9 million.
  • The largest annual shift saw Current Assets plummeted 44.24% in 2022 before it soared 354.46% in 2023.
  • Over 5 years, Current Assets stood at $77.8 million in 2022, then soared by 242.3% to $266.2 million in 2023, then increased by 19.53% to $318.1 million in 2024, then surged by 49.27% to $474.9 million in 2025, then fell by 2.47% to $463.1 million in 2026.
  • Business Quant data shows Current Assets for ELVN at $463.1 million in Q1 2026, $474.9 million in Q4 2025, and $482.7 million in Q3 2025.